<DOC>
	<DOCNO>NCT01320943</DOCNO>
	<brief_summary>Withdrawal antiviral therapy result hepatic alanine aminotransferase ( ALT ) flare Hepatitis B Virus ( HBV ) replication resume ; however , participant , flare exacerbate chronic hepatitis temporarily also result viral clearance . Hepatic flare common stop anti-HBV therapy . Only participant already treatment tenofovir disoproxil fumarate ( TDF ) monotherapy TDF combination lamivudine emtricitabine least 4 year achieve maintain virologic suppression ( &lt; 400 copies/mL ) 3.5 year include study . One treatment arm stop TDF therapy treatment arm continue TDF therapy . Participants Stop TDF arm monitor closely special focus biochemical flare ( especially ALT increase ) virological relapse ( Hepatitis B viral load increase ) . If participant Stop TDF arm exceed one predefined limit flare relapse , TDF reinstituted . The study ass Hepatitis B surface antigen ( HBsAg ) loss ( i.e . specific Hepatitis B virus component longer detectable ) seroconversion ( occurrence Hepatitis B surface antibody , specific antibody usually occur HBsAg loss ) rate study duration . The percentage participant need restart TDF therapy Stop TDF arm also evaluate .</brief_summary>
	<brief_title>Stopping TDF Treatment After Long Term Virologic Suppression HBeAg-negative CHB</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Tin Fluorides</mesh_term>
	<criteria>Chronic hepatitis B , hepatitis B eantigen negative , hepatitis B eantibody positive , hepatitis B surface antigenpositive Hepatitis B e Antigen ( HBeAg ) negative begin TDF therapy ( i.e . TDF monotherapy combination TDF + lamivudine TDF + emtricitabine ) Received continuous TDF therapy ( i.e . TDF monotherapy combination TDF + lamivudine TDF + emtricitabine ) treatment least 4 year prior screen . If TDF use combination lamivudine emtricitabine , lamivudine emtricitabine must stop least 12 week prior screen Documented hepatitis B virus DNA ( HBV DNA ) &lt; 400 copies/mL least 3.5 year prior screen screen ALT within normal range αfetoprotein ( AFP ) &lt; = 50 ng/mL Calculated creatinine clearance &gt; = 70 mL/min CockcroftGault formula use ideal body weight &lt; = 10 kPa Fibroscan assessment A negative serum pregnancy test female subject Adult subject &gt; = 18 year age Known cirrhosis Evidence fibrosis &gt; = Stage 3 ( METAVIR ) liver biopsy Fibroscan &gt; 10 kPa within 6 month prior screen Documentation confirm episode ( i.e. , 2 consecutive value ) HBV DNA &gt; 400 copies/mL within 3.5 year prior screen History decompensated liver disease ( define direct [ conjugate ] bilirubin &gt; 1.5 x upper limit normal , prothrombin time ( PT ) &gt; 1.5 x upper limit normal , platelet &lt; 75,000/mm³ , serum albumin &lt; 3.0 g/dL History clinical hepatic decompensation judgement investigator Evidence hepatocellular carcinoma Significant bone disease ( judgment investigator ) Serological evidence coinfection human immunodeficiency virus ( HIV ) , hepatitis C virus , hepatitis D infection Known hypersensitivity TDF , metabolites , formulation excipients Concomitant therapy disallow medication History malignant disease Lactating females Females wish become pregnant duration stud Subjects participate another clinical trial enrol discretion Medical Monitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>stop oral antiviral therapy</keyword>
	<keyword>HBsAg loss</keyword>
	<keyword>seroconversion</keyword>
	<keyword>restart oral antiviral therapy</keyword>
</DOC>